Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model

Prostate

Volumn 73, Issue 10, 2013, Pages 1123-1133

  Gharaee Kermani, Mehrnaz ^a   Rodriguez Nieves, Jose A ^a,b   Mehra, Rohit ^a   Vezina, Chad A ^c   Sarma, Aruna V ^a   MacOska, Jill A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

bladder; collagen; diet; fat; prostate

Indexed keywords

INSULIN;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FIBROSIS; GLUCOSE TOLERANCE TEST; INSULIN BLOOD LEVEL; LIPID DIET; LOW FAT DIET; LOWER URINARY TRACT FIBROSIS; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION; MICTURITION DISORDER; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, FAT-RESTRICTED; DIET, HIGH-FAT; DIETARY FATS; DISEASE MODELS, ANIMAL; FIBROSIS; GLUCOSE TOLERANCE TEST; INSULIN; LOWER URINARY TRACT SYMPTOMS; MALE; MICE; OBESITY; PROSTATE;

EID: 84878435764     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22662     Document Type: Article

References (48)

1. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB,. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54 (9): 935-944.
2. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RD, Jimenez Cruz F, Jonas U, MacRae K, Pientka L, Rutten FF, van Schayck CP, Speakman MJ, Tiellac P, Tubaro A, Vallencien G, Vela Navarrete R,. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-The Triumph project. Eur Urol 2002; 42 (4): 323-328.
3. Guess HA,. Benign prostatic hyperplasia: Antecedents and natural history. Epidemiol Rev 1992; 14: 131-153.
4. McVary KT,. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007; 29 (3): 387-398.
5. Garber AJ,. Obesity and type 2 diabetes: Which patients are at risk ? Diabetes Obes Metab 2012; 14 (5): 399-408.
6. Centers for Disease Control and Prevention National Diabetes Fact Sheet: National estimates and general information on diabetes and prediabetes in the United States 2011. Atlanta, GA: US Department of Health and Human; Services, Centers for Disease Control and Prevention; 2011.
7. Parsons JK,. Benign prostatic hyperplasia and male lower urinary tract symptoms: Epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010; 5 (4): 212-218.
8. Parsons JK, Sarma AV, McVary K, Wei JT,. Obesity and benign prostatic hyperplasia: Clinical connections, emerging etiological paradigms and future directions. J Urol 2013; 189 (1 Suppl): S102-S106.
9. Khoo J, Piantadosi C, Duncan R, Worthley SG, Jenkins A, Noakes M, Worthley MI, Lange K, Wittert GA,. Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men. J Sex Med 2011; 8 (10): 2868-2875.
10. Klein BE, Klein R, Lee KE, Bruskewitz RC,. Correlates of urinary symptom scores in men. Am J Public Health 1999; 89 (11): 1745-1748. PMCID: 1508982.
11. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, James SA, Cooney KA, Doerr KM, Montie JE, Schottenfeld D,. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003; 157 (10): 906-914.
12. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M,. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000; 163 (6): 1725-1729.
13. Koskimaki J, Hakama M, Huhtala H, Tammela TL,. Association of non-urological diseases with lower urinary tract symptoms. Scand J Urol Nephrol 2001; 35 (5): 377-381.
14. Dib PT, Trigo-Rocha F, Gomes CM, Srougi M,. Urodynamic evaluation in diabetic patients with prostate enlargement and lower urinary tract symptoms. Urol Int 2008; 80 (4): 378-382.
15. Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J, Girman CJ, Lieber MM, Herman W, Macoska J, Montie JE, Jacobsen SJ,. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care 2008; 31 (3): 476-482.
16. Ma J, Gharaee-Kermani M, Kunju L, Hollingsworth JM, Adler J, Arruda EM, Macoska JA,. Prostatic fibrosis is associated with lower urinary tract symptoms. J Urol 2012; 188 (4): 1375-1381. PMCID: 3485634.
17. Takeda T, Hosokawa M, Higuchi K,. Senescence-accelerated mouse (SAM): A novel murine model of senescence. Exp Gerontol 1997; 32 (1-2): 105-109.
18. Takeda T, Matsushita T, Kurozumi M, Takemura K, Higuchi K, Hosokawa M,. Pathobiology of the senescence-accelerated mouse (SAM). Exp Gerontol 1997; 32 (1-2): 117-127.
19. Sugimura Y, Sakurai M, Hayashi N, Yamashita A, Kawamura J,. Age-related changes of the prostate gland in the senescence-accelerated mouse. Prostate 1994; 24 (1): 24-32.
20. Niimi K, Takahashi E, Itakura C,. Adiposity-related biochemical phenotype in senescence-accelerated mouse prone 6 (SAMP6). Comp Med 2009; 59 (5): 431-436. PMCID: 2771603.
21. Hodges SJ, Zhou G, Deng FM, Aboushwareb T, Turner C, Andersson KE, Santago P, Case D, Sun TT, Christ GJ,. Voiding pattern analysis as a surrogate for cystometric evaluation in uroplakin II knockout mice. J Urol 2008; 179 (5): 2046-2051.
22. Adler J, Swanson SD, Schmiedlin-Ren P, Higgins PD, Golembeski CP, Polydorides AD, McKenna BJ, Hussain HK, Verrot TM, Zimmermann EM,. Magnetization transfer helps detect intestinal fibrosis in an animal model of Crohn disease. Radiology 2011; 259 (1): 127-135. PMCID: 3064818.
23. Adler, Imatinib decreases bowel wall fibrosis, reduces inflammatory cytokines and pro-fibrotic factors in peptidoglican-polysaccharide rat model of Crohn's disease. 2010.
24. Nickel JC, Downey J, Young I, Boag S,. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84 (9): 976-981.
25. Roehrborn C, Kaplan S, Noble W, Lucia M, Slawin K, McVary K, Kusek J, Nyberg L,. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPE: Results from the MTOPS study. AUA Meeting. 2005; Abstract # 1277.
26. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, Maillé P, Allory Y, de la Taille A,. Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 2009; 69 (16): 1774-1780.
27. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP,. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer ? J Urol 2008; 179 (5): 1736-1740. PMCID: 2661538.
28. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE,. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest 1992; 66 (1): 96-107.
29. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, Paikl D, Ecker RC, Hrachowitz K, Kramer G, Lee C, Marberger M,. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest 2003; 83 (8): 1131-1146.
30. Kramer G, Mitteregger D, Marberger M,. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease ? Eur Urol 2007; 51 (5): 1202-1216.
31. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA,. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging Cell 2005; 4 (6): 291-298.
32. Begley LA, Kasina S, MacDonald J, Macoska JA,. The inflammatory microenvironment of the aging prostate facilitates cellular proliferation and hypertrophy. Cytokine 2008; 43 (2): 194-199. PMCID: 2538565.
33. Macoska JA,. Chemokines and BPH/LUTS. Differentiation 2011; 82 (4-5): 253-260.
34. Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA,. CXCL5 promotes prostate cancer progression. Neoplasia 2008; 10 (3): 244-254. PMCID: 2262133.
35. Begley LA, MacDonald JW, Day ML, Macoska JA,. CXCL12 activates a robust transcriptional response in human prostate epithelial cells. J Biol Chem 2007; 282 (37): 26767-26774.
36. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR,. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; 8 (9): 2912-2923.
37. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR,. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology 2008; 72 (1): 205-213.
38. Schauer IG, Ressler SJ, Rowley DR,. Keratinocyte-derived chemokine induces prostate epithelial hyperplasia and reactive stroma in a novel transgenic mouse model. Prostate 2009; 69 (4): 373-384.
39. Lumeng CN, Saltiel AR,. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121 (6): 2111-2117.
40. Harwood HJ Jr., The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology 2012; 63 (1): 57-75.
41. Taube A, Schlich R, Sell H, Eckardt K, Eckel J,. Inflammation and metabolic dysfunction: Links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012; 302 (11): H2148-H2165.
42. Pahl HL,. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18 (49): 6853-6866.
43. Shoelson SE, Lee J, Goldfine AB,. Inflammation and insulin resistance. J Clin Invest 2006; 116 (7): 1793-1801. PMCID: 1483173.
44. Scotton CJ, Chambers RC,. Molecular targets in pulmonary fibrosis: The myofibroblast in focus. Chest 2007; 132 (4): 1311-1321.
45. Wynn TA,. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214 (2): 199-210.
46. Spencer M, Yao-Borengasser A, Unal R, Rasouli N, Gurley CM, Zhu B, Peterson CA, Kern PA,. Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation. Am J Physiol Endocrinol Metab 2010; 299 (6): E1016-E1027.
47. Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA,. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS ONE 2012; 7 (11): e49278.
48. Lecka-Czernik B, Moerman EJ, Shmookler Reis RJ, Lipschitz DA,. Cellular and molecular biomarkers indicate precocious in vitro senescence in fibroblasts from SAMP6 mice. Evidence supporting a murine model of premature senescence and osteopenia. J Gerontol A Biol Sci Med Sci 1997; 52 (6): B331-B336.